“Despite predictions that our actions would increase rates and destabilize markets, the opposite has happened,” says CMS Administrator Seema Verma.
Evofem Biosciences is on the cusp of releasing a revolutionary birth control product. But before the FDA gives its approval, this small biopharma has to navigate two very different clinical trials.
A discussion regarding the challenging decisions Pfenex made in the past year regarding its biosimilar pipeline and the company’s efforts getting its teriparatide follow-on ready for the 505(b)(2) pathway.
The larger BioHealth Capital Region, of which the I-270 biotech corridor is a part, currently ranks as the fifth largest biotech hub in the U.S. with 39,000 people employed by the industry.
Falsified medicines are a critical challenge to the safety of patients and to the reputation of the pharmaceutical industry. Serialization is a major step toward drug safety across the EU but has brought with it a set of challenges that national authorities and companies are tackling.
Liz Barrett, CEO of Novartis Oncology, discusses taking a proactive approach toward mentoring tomorrow’s leaders.
Novartis Oncology CEO, Liz Barrett, on career advancement and family, a common challenge for women in the workplace.
Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, provides a preview as to his approach to transformation the company’s product development and manufacturing operations, along with insight into the world of biopharmaceutical outsourcing.
